BR9510420A - Azetidin-2-onas substituìdas para o tratamento de aterosclerose - Google Patents

Azetidin-2-onas substituìdas para o tratamento de aterosclerose

Info

Publication number
BR9510420A
BR9510420A BR9510420-8A BR9510420A BR9510420A BR 9510420 A BR9510420 A BR 9510420A BR 9510420 A BR9510420 A BR 9510420A BR 9510420 A BR9510420 A BR 9510420A
Authority
BR
Brazil
Prior art keywords
azetidin
ones
replaced
atherosclerosis
treatment
Prior art date
Application number
BR9510420-8A
Other languages
English (en)
Inventor
Deirdre Mary Bernadette Hickey
Colin Andrew Leach
Robert John Ife
David Graham Tew
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9510420A publication Critical patent/BR9510420A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"AZETIDIN-2-ONAS SUBSTITUìDAS PARA O TRATAMENTO DE ATEROSCLEROSE". Compostos de fórmula (I) em que R1 e R2 podem ser iguais ou diferentes, é cada selecionado dentre hidrogênio, halogênio, ou alquila C1-8, R3 é arila ou aril alquila C(1-4), que podem ser opcionalmente substituídos, X é um grupo ligador, Y é um grupo arila opcionalmente substituído, e n é 0, 1 ou 2, são inibidores da enzima Lp-PLA2 e seu uso no tratamento de aterosclerose.
BR9510420-8A 1994-12-22 1995-12-20 Azetidin-2-onas substituìdas para o tratamento de aterosclerose BR9510420A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds
PCT/EP1995/005130 WO1996019451A1 (en) 1994-12-22 1995-12-20 Substituted azetidin-2-ones for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
BR9510420A true BR9510420A (pt) 2004-04-20

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9510420-8A BR9510420A (pt) 1994-12-22 1995-12-20 Azetidin-2-onas substituìdas para o tratamento de aterosclerose

Country Status (24)

Country Link
US (1) US5990102A (pt)
EP (1) EP0799200A1 (pt)
JP (1) JPH11500415A (pt)
CN (1) CN1175246A (pt)
AP (1) AP9701007A0 (pt)
AR (1) AR002012A1 (pt)
AU (1) AU704407B2 (pt)
BG (1) BG101687A (pt)
BR (1) BR9510420A (pt)
CA (1) CA2208530A1 (pt)
CZ (1) CZ192297A3 (pt)
DZ (1) DZ1958A1 (pt)
FI (1) FI972584A (pt)
HU (1) HUT77089A (pt)
IL (1) IL116485A0 (pt)
MA (1) MA23834A1 (pt)
MX (1) MX9704736A (pt)
NO (1) NO972909L (pt)
NZ (1) NZ298416A (pt)
OA (1) OA10737A (pt)
PL (1) PL320937A1 (pt)
SK (1) SK80397A3 (pt)
TR (1) TR199501655A2 (pt)
WO (1) WO1996019451A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9609445A (pt) * 1995-07-01 1999-04-06 Smithkline Beecham Plc Derivados de azetidinona no tratamento de aterosclerose
EP0865429A1 (en) * 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
WO1997021675A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
IL126696A0 (en) * 1996-04-26 1999-08-17 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
HU229479B1 (en) 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
WO2005107767A2 (en) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP5277243B2 (ja) 2007-05-11 2013-08-28 トーマス・ジェファーソン・ユニバーシティ 神経変性疾患および障害を治療および阻止する方法
WO2008141176A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
PE20140421A1 (es) 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
AU2012289492B2 (en) 2011-07-27 2016-02-04 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
KR20140059204A (ko) 2011-07-27 2014-05-15 글락소 그룹 리미티드 비시클릭 피리미돈 화합물
BR112015017768A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
TW201443054A (zh) 2013-01-25 2014-11-16 Glaxosmithkline Ip Dev Ltd 化合物
WO2015179293A1 (en) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule activators and inhibitors of lecithin: cholesterol acyltransferase
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
IL292668A (en) 2019-11-09 2022-07-01 Shanghai Simr Biotechnology Co Ltd A tricyclic derivative of dihydroimidazopyrimidone, its preparation method, pharmaceutical preparation and its use
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010358A1 (en) * 1978-09-20 1980-04-30 Glaxo Group Limited Beta-lactam compounds, processes for their preparation, compositions containing them, intermediates of use in their preparation and methods for the production thereof
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO972909D0 (no) 1997-06-20
FI972584A (fi) 1997-08-19
AR002012A1 (es) 1998-01-07
CZ192297A3 (en) 1997-11-12
AU4389896A (en) 1996-07-10
IL116485A0 (en) 1996-08-04
DZ1958A1 (fr) 2002-02-17
NZ298416A (en) 1999-03-29
OA10737A (en) 2002-12-10
TR199501655A2 (tr) 1996-07-21
BG101687A (en) 1998-02-27
WO1996019451A1 (en) 1996-06-27
FI972584A0 (fi) 1997-06-17
JPH11500415A (ja) 1999-01-12
NO972909L (no) 1997-08-20
CA2208530A1 (en) 1996-06-27
MA23834A1 (fr) 1996-10-01
AU704407B2 (en) 1999-04-22
US5990102A (en) 1999-11-23
EP0799200A1 (en) 1997-10-08
SK80397A3 (en) 1998-01-14
AP9701007A0 (en) 1997-07-31
PL320937A1 (en) 1997-11-10
CN1175246A (zh) 1998-03-04
HUT77089A (hu) 1998-03-02
MX9704736A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
BR9510420A (pt) Azetidin-2-onas substituìdas para o tratamento de aterosclerose
BR9806752A (pt) Ftalazinonas.
DK1019368T3 (da) Acylsulfamoylbenzoesyreamider, nytteplantebeskyttelsesmidler indeholdende disse samt fremgangsmåder til deres fremstilling
BR9611175A (pt) Compostos ou suas composições e uso dos mesmo
DE69739853D1 (de) Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
DE69719350T2 (de) 2-pyrimidinamin derivaten und verfahrens zu deren herstellung
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
DE59508773D1 (de) Dihydrobenzofurane
BR0010220A (pt) Compostos de pirimidinona
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
ES2147399T3 (es) Nuevos derivados de 2,3,5-trimetil-4-hidroxianilidas, su preparacion y su aplicacion terapeutica.
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
PT920426E (pt) Novos derivados de tiazole com efeito inibidor de fosfodiesterase
CO4700298A1 (es) Derivados de 3-fenilisoquinoleina-1 (2h)-ona, su preparacion y su aplicacion en la terapeutica
BR0015018A (pt) Agente herbicida
AR246162A1 (es) Composicion antimicrobiana
NO972938D0 (no) Farmasöytiske piperazinforbindelser
ES2152563T3 (es) Procedimiento para preparar derivados de dihidroxipirimidina.
BR9912307A (pt) Inibidores fkbp
NO952427D0 (no) Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5
BR0016115A (pt) Derivados peptìdicos de acriloìla, processo para sua preparação e seu uso como agentes inibidores de tumor
DE69017627D1 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.
DK600585D0 (da) 2,3-diamino-2,3-didesoxyhexosederivater, fremgangsmaade til fremstilling deraf samt anvendelse deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]